Decoding the bidirectional relationship between gut microbiota and COVID-19

[1]  V. Aeri,et al.  Deciphering the role of gut metabolites in non-alcoholic fatty liver disease , 2022, Critical reviews in microbiology.

[2]  Michael J. Patton,et al.  Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis , 2022, International journal of molecular sciences.

[3]  K. Kohli,et al.  Gut microbiota as an emerging therapeutic avenue for the treatment of non-alcoholic fatty liver disease. , 2021, Current pharmaceutical design.

[4]  J. Ellory,et al.  B0AT1 Amino Acid Transporter Complexed With SARS-CoV-2 Receptor ACE2 Forms a Heterodimer Functional Unit: In Situ Conformation Using Radiation Inactivation Analysis , 2021, Function.

[5]  Michael J. Patton,et al.  Plasma microbiome in COVID-19 subjects: an indicator of gut barrier defects and dysbiosis , 2021, bioRxiv.

[6]  K. Chow,et al.  Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 , 2021, Gut.

[7]  Adil Hassan,et al.  SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role , 2020, Biomedicine & Pharmacotherapy.

[8]  B. Stevens.  TMPRSS2 and ADAM17 interactions with ACE2 complexed with SARS-CoV-2 and B0AT1 putatively in intestine, cardiomyocytes, and kidney , 2020, bioRxiv.

[9]  B. Stevens,et al.  Amino acid transporter B0AT1 influence on ADAM17 interactions with SARS-CoV-2 receptor ACE2 putatively expressed in intestine, kidney, and cardiomyocytes , 2020, bioRxiv.

[10]  Sanjay K. S. Patel,et al.  Diet, Gut Microbiota and COVID-19 , 2020, Indian Journal of Microbiology.

[11]  H. Nikzad,et al.  The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies , 2020, Virology.

[12]  C. Pepine,et al.  ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2. , 2020, Hypertension.

[13]  K. Adeli,et al.  Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression , 2020, Physiology.

[14]  Jingjing Fu,et al.  Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor , 2020, Proceedings of the National Academy of Sciences.

[15]  Zigui Chen,et al.  Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19 , 2020, Gut.

[16]  F. Reis,et al.  ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities – Role of gut microbiota dysbiosis , 2020, Ageing Research Reviews.

[17]  M. Boulton,et al.  SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes , 2020, Diabetes.

[18]  M. Raizada,et al.  SARS-CoV-2 Receptor ACE-2 (Angiotensin-Converting Enzyme 2) Is Upregulated in Colonic Organoids From Hypertensive Rats , 2020, Hypertension.

[19]  Mohammad K. Haidar,et al.  Atorvastatin-loaded nanosprayed chitosan nanoparticles for peripheral nerve injury , 2020 .

[20]  Yuan Shi,et al.  Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections , 2020, Frontiers in Microbiology.

[21]  Lanjuan Li,et al.  Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  G. Lippi,et al.  Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence , 2020, Clinical chemistry and laboratory medicine.

[23]  T. Liang,et al.  [Management of COVID-19: the Zhejiang experience]. , 2020, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.

[24]  S. Taghavi,et al.  COVID-19 and the Gut Microbiome: More than a Gut Feeling , 2020, mSystems.

[25]  S. Ng,et al.  Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization , 2020, Gastroenterology.

[26]  D. Dhar,et al.  Gut microbiota and Covid-19- possible link and implications , 2020, Virus Research.

[27]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[28]  Xiaosheng Wang,et al.  Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues , 2020, Infectious Diseases of Poverty.

[29]  R. José,et al.  COVID-19 cytokine storm: the interplay between inflammation and coagulation , 2020, The Lancet Respiratory Medicine.

[30]  Adolfo B Poma,et al.  Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment , 2020, Journal of biomolecular structure & dynamics.

[31]  Xuexian Fang,et al.  Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis , 2020, Research.

[32]  Rong Lin,et al.  Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes , 2020, The American journal of gastroenterology.

[33]  Juan A. Siordia,et al.  Epidemiology and clinical features of COVID-19: A review of current literature , 2020, Journal of Clinical Virology.

[34]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[35]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[36]  M. Zuin,et al.  Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome , 2020, Journal of Clinical Virology.

[37]  Juan Du,et al.  Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study , 2020, European Respiratory Journal.

[38]  Yan Liu,et al.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.

[39]  Centers for Disease Control and Prevention CDC COVID-19 Response Team.  Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[40]  C. Mantzoros,et al.  Commentary: COVID-19 in patients with diabetes , 2020, Metabolism.

[41]  O. Pfister,et al.  SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? , 2020, European heart journal.

[42]  Lei Liu,et al.  Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China , 2020, Diabetes Care.

[43]  Bo Li,et al.  Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China , 2020, Clinical Research in Cardiology.

[44]  Michael Roth,et al.  Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.

[45]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[46]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[47]  A. Nishiyama,et al.  Recent Research Advances in Renin-Angiotensin-Aldosterone System Receptors , 2020, Current Hypertension Reports.

[48]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[49]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[50]  Ping Chen,et al.  Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission , 2020, Science China Life Sciences.

[51]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[52]  S. Li Calzi,et al.  Bone Marrow-Derived Cells Restore Functional Integrity of the Gut Epithelial and Vascular Barriers in a Model of Diabetes and ACE2 Deficiency. , 2019, Circulation research.

[53]  S. Taleb.  Tryptophan Dietary Impacts Gut Barrier and Metabolic Diseases , 2019, Front. Immunol..

[54]  B. Marsland,et al.  Microbes, metabolites, and the gut–lung axis , 2019, Mucosal Immunology.

[55]  A. Gasbarrini,et al.  Gut microbiota and aging. , 2018, European review for medical and pharmacological sciences.

[56]  S. Mande,et al.  Diet, Microbiota and Gut-Lung Connection , 2018, Front. Microbiol..

[57]  N. Radosevic-Robin,et al.  Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer , 2017, Journal of oncology.

[58]  C. Bernardazzi,et al.  Diet and microbiota in inflammatory bowel disease: The gut in disharmony , 2017, World journal of gastroenterology.

[59]  Sejin Oh,et al.  Mucoadhesion vs mucus permeability of thiolated chitosan polymers and their resulting nanoparticles using a quartz crystal microbalance with dissipation (QCM-D). , 2016, Colloids and surfaces. B, Biointerfaces.

[60]  B. Marsland,et al.  The Gut-Lung Axis in Respiratory Disease. , 2015, Annals of the American Thoracic Society.

[61]  T. van der Poll,et al.  The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia , 2015, Gut.

[62]  D. Welsh,et al.  Regulation of lung immunity and host defense by the intestinal microbiota , 2015, Front. Microbiol..

[63]  Bernard M. Corfe,et al.  Dysbiosis of the gut microbiota in disease , 2015, Microbial ecology in health and disease.

[64]  E. Wouters,et al.  Disturbed intestinal integrity in patients with COPD: effects of activities of daily living. , 2014, Chest.

[65]  E. Horváth-Puhó,et al.  Cancer Risk in Inflammatory Bowel Disease According to Patient Phenotype and Treatment: A Danish Population-Based Cohort Study , 2013, The American Journal of Gastroenterology.

[66]  X. Deng,et al.  Gut-lung crosstalk in pulmonary involvement with inflammatory bowel diseases. , 2013, World journal of gastroenterology.

[67]  S. Mazmanian,et al.  Innate immune recognition of the microbiota promotes host-microbial symbiosis , 2013, Nature Immunology.

[68]  Sang-Uk Seo,et al.  Role of the gut microbiota in immunity and inflammatory disease , 2013, Nature Reviews Immunology.

[69]  K. Honda,et al.  Intestinal commensal microbes as immune modulators. , 2012, Cell host & microbe.

[70]  P. Rosenstiel,et al.  ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation , 2012, Nature.

[71]  D. Levy,et al.  Induction and function of type I and III interferon in response to viral infection. , 2011, Current opinion in virology.

[72]  N. Talley,et al.  Pulmonary-intestinal cross-talk in mucosal inflammatory disease , 2011, Mucosal Immunology.

[73]  Christian Drosten,et al.  Cleavage and Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by Human Airway Trypsin-Like Protease , 2011, Journal of Virology.

[74]  R. Curi,et al.  Regulation of Inflammation by Short Chain Fatty Acids , 2011, Nutrients.

[75]  A. Margolles,et al.  Distinct Bifidobacterium strains drive different immune responses in vitro. , 2010, International journal of food microbiology.

[76]  G. Whittaker,et al.  Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites , 2009, Proceedings of the National Academy of Sciences.

[77]  Robert Kleta,et al.  Tissue-Specific Amino Acid Transporter Partners ACE2 and Collectrin Differentially Interact With Hartnup Mutations , 2008, Gastroenterology.

[78]  P. Gopal,et al.  Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. , 2001, The American journal of clinical nutrition.

[79]  T. Ichinohe,et al.  Response of host inflammasomes to viral infection. , 2015, Trends in microbiology.